DR. DAVID H BARAD, M.D.
Medical Practice at 69 St, New York, NY
License number
New York 140352-1
Category
Medical Practice
Type
Reproductive Endocrinology
License number
New York 25MA08029900
Category
Medical Practice
Type
Reproductive Endocrinology
Address
Address
2
21 E 69Th St, New York, NY 10021
26 Kinkaid Ave, Closter, NJ 07624
26 Kinkaid Ave, Closter, NJ 07624
Phone
(212) 994-4400
(212) 994-4499 (Fax)
(201) 784-1218
(212) 994-4499 (Fax)
(201) 784-1218
Personal information
See more information about DAVID H BARAD at radaris.comName
Address
Phone
223 Howard Ave, Orangeburg, NY 10962
26 Kinkaid Ave, Closter, NJ 07624
PO Box 985, Harriman, NY 10926
Professional information
Dr. David H Barad, New York NY - MD (Doctor of Medicine)
Specialties:
Reproductive Endocrinology & Infertility
Address:
Center Human Reproduction
21 E 69Th St, New York 10021
(212) 994-4400 (Phone)
21 E 69Th St, New York 10021
(212) 994-4400 (Phone)
Certifications:
Fertility & Reproductive Endocrinology, 2009, Obstetrics & Gynecology, 2008
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Rutgers Medical School
Graduated: 1978
Metro Hospital
Colum P&S
Brigham Womens Hospital
Rutgers Medical School
Graduated: 1978
Metro Hospital
Colum P&S
Brigham Womens Hospital
David Hyman Barad, New York NY
Specialties:
OB-GYN
Address:
21 E 69Th St, New York, NY 10021
1111 Amsterdam Ave, New York, NY 10025
1111 Amsterdam Ave, New York, NY 10025
Education:
CMDNJ-Rutgers - Doctor of Medicine
Brigham & Women's Hospital - Fellowship - Reproductive Endocrinology
New York Presbyterian Hospital-Columbia Presbyterian Center - Residency - Obstetrics and Gynecology
Brigham & Women's Hospital - Fellowship - Reproductive Endocrinology
New York Presbyterian Hospital-Columbia Presbyterian Center - Residency - Obstetrics and Gynecology
Board certifications:
American Board of Obstetrics and Gynecology Certification in Obstetrics & Gynecology, American Board of Obstetrics and Gynecology Sub-certificate in Reproductive Endocrinology/Infertility (Obstetrics & Gynecology)
Method Of Improving Cumulative Embryo Score And Quantity Of Fertilized Ooytes, Increasing Euploidy Rate And Of Normalizing Ovarian Function Using An Androgen Such As Dehydroepiandrosterone
US Patent:
2006008, Apr 27, 2006
Filed:
Nov 8, 2005
Appl. No.:
11/269310
Inventors:
Norbert Gleicher - Chicago IL, US
David Barad - Closter NJ, US
Dwyn Harben - Bryn Mawr PA, US
David Barad - Closter NJ, US
Dwyn Harben - Bryn Mawr PA, US
International Classification:
A61K 31/56
US Classification:
514170000, 800021000
Abstract:
A method of improving cumulative embryo score may comprise administering an androgen to a human female, for example, DHEA, for at least about four consecutive months followed by harvesting and fertilizing oocytes and forming embryos. Between about 50 mg and about 100 mg of DHEA may be administered to a human female per day. Moreover, a method of increasing the quantity of fertilized oocytes in one cycle of in vitro fertilization may comprise administering an androgen to a human female for at least about four consecutive months, harvesting and fertilizing the oocytes. Furthermore, a method of increasing the quantity of day 3 embryos from one cycle of in vitro fertilization may comprise administering an androgen for at least about four consecutive months, harvesting and fertilizing the oocytes and forming day 3 embryos. A method of normalizing ovarian DHEA also may include administering an androgen for at least about four consecutive months. A method of increasing the euploidy rate in embryos may include administering an androgen for at least about four consecutive weeks.
Androgen Treatment In Females
US Patent:
2007015, Jul 5, 2007
Filed:
Mar 1, 2007
Appl. No.:
11/680973
Inventors:
Norbert GLEICHER - Chicago IL, US
David Barad - Closter NJ, US
Dwyn Harben - Bryn Mawr PA, US
David Barad - Closter NJ, US
Dwyn Harben - Bryn Mawr PA, US
International Classification:
A61K 31/57
US Classification:
514177000
Abstract:
A method of improving cumulative embryo score may comprise administering an androgen to a human female, for example, DHEA, for at least about four consecutive months followed by harvesting and fertilizing oocytes and forming embryos. Between about 50 mg and about 100 mg of DHEA may be administered to a human female per day. Moreover, a method of increasing the quantity of fertilized oocytes in one cycle of in vitro fertilization may comprise administering an androgen to a human female for at least about four consecutive months, harvesting and fertilizing the oocytes. Furthermore, a method of increasing the quantity of day 3 embryos from one cycle of in vitro fertilization may comprise administering an androgen for at least about four consecutive months, harvesting and fertilizing the oocytes and forming day 3 embryos. A method of normalizing ovarian DHEA also may include administering an androgen for at least about four consecutive months. A method of increasing the rate and number of euploid oocytes may include administering an androgen for at least about four consecutive weeks. In addition, a method of increasing male fetus sex ratio may comprise raising baseline androgen levels in a female prior to or at time of embryo implantation.
Analyzing The Fmr1 Gene
US Patent:
2011002, Jan 27, 2011
Filed:
Jul 23, 2009
Appl. No.:
12/508295
Inventors:
Norbert GLEICHER - Chicago IL, US
David H. BARAD - Closter NJ, US
David H. BARAD - Closter NJ, US
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
A method of predicting a degree of risk of early ovarian aging of a young female. The method includes analyzing the female's FMR1 gene, wherein the FMR1 gene has a first allele and a second allele; determining the number of triple CGG repeats on each of the first and second alleles; defining a normal range of triple CGG repeats; comparing the number of triple CGG repeats on each of the first and second alleles to the normal range. If the triple CGG repeat numbers for both of the first and second alleles are within the normal range, then the female is at minimal risk for early ovarian aging. If the triple CGG repeat number for one of the first and second alleles is outside of the normal range and the other one of the first and second alleles is within the normal range, then the first and second alleles are heterozygous and the female is at increased risk for early ovarian aging. If the triple CGG repeat numbers for both of the first and second alleles are outside of the normal range, then the first and second alleles are homozygous and the female is also at an increased risk for early ovarian aging.
Analyzing The Fmr1 Gene
US Patent:
2011015, Jun 30, 2011
Filed:
Mar 8, 2011
Appl. No.:
13/043199
Inventors:
Norbert GLEICHER - Chicago IL, US
David H. Barad - Closter NJ, US
David H. Barad - Closter NJ, US
International Classification:
C12Q 1/68
US Classification:
435 611
Abstract:
A method of predicting a degree of risk of autoimmunity in a human female is disclosed. The method may include analyzing the female's FMR1 gene, wherein the FMR1 gene has a first allele and a second allele, determining the number of triple CGG repeats on each of the first and second alleles; defining a normal range of triple CGG repeats; and comparing the number of triple CGG repeats on each of the first and second alleles to the normal range. If the triple CGG repeat number for one of the first and second alleles is in the normal range and the triple CGG repeat number for the other one of the first and second alleles is less than the lower boundary of the normal range, then the female is at increased risk of autoimmunity. Additionally, a method of predicting pregnancy chances for a human female is disclosed. The method may include analyzing the female's FMR1 gene, wherein the FMR1 gene has a first allele and a second allele; determining the number of triple CGG repeats on each of the first and second alleles; defining a normal range of triple CGG repeats; and comparing the number of triple CGG repeats on each of the first and second alleles to the normal range. If the triple CGG repeat number for one of the first and second alleles is in the normal range and the triple CGG repeat number for the other one of the first and second alleles is less than the lower boundary of the normal range, then the female has decreased chances of pregnancy.
Androgen Treatment In Females
US Patent:
8067400, Nov 29, 2011
Filed:
May 20, 2008
Appl. No.:
12/123877
Inventors:
Norbert Gleicher - Chicago IL, US
David H. Barad - Closter NJ, US
Dwyn V. Harben - Bryn Mawr PA, US
David H. Barad - Closter NJ, US
Dwyn V. Harben - Bryn Mawr PA, US
Assignee:
American Infertility of New York - New York NY
International Classification:
A61K 31/56, A61P 15/08, A61K 31/5685
US Classification:
514170, 514169
Abstract:
A method of improving cumulative embryo score may comprise administering an androgen to a human female for at least about four consecutive months followed by harvesting and fertilizing oocytes and forming embryos. A method of increasing the quantity of fertilized oocytes in one cycle of in vitro fertilization may comprise administering an androgen to a human female for at least about four consecutive months, harvesting and fertilizing the oocytes. A method of normalizing ovarian DHEA may include administering an androgen for at least about four consecutive months. A method of decreasing the time to pregnancy and increasing the rate of pregnancy by administering an androgen for at least about two months. A method of decreasing miscarriage rates may comprise administering an androgen for at least about two months to a female. Moreover, a method of decreasing aneuploidy rates in human embryos may comprise administering an androgen to a female for at least about two months.
Androgen Treatment In Females
US Patent:
2011020, Aug 25, 2011
Filed:
Mar 8, 2011
Appl. No.:
13/043266
Inventors:
Norbert Gleicher - Chicago IL, US
David H. Barad - Closter NJ, US
David H. Barad - Closter NJ, US
International Classification:
A61K 31/566, A61P 15/08, C12Q 1/68
US Classification:
514179, 435 61, 435 611
Abstract:
The present invention is directed to a method of using dehydroepiandrosterone to treat a human female with diminished ovarian reserve. The method includes administering about 25 milligrams three times a day of dehydroepiandrosterone per day to the female for at least four weeks to reduce human embryo aneuploidy. The present invention further is directed to a method of treating a human female with diminished ovarian reserve to improve the female's diminished ovarian reserve.
Analyzing The Fmr1 Gene
US Patent:
2012012, May 24, 2012
Filed:
Jan 27, 2012
Appl. No.:
13/360349
Inventors:
Norbert GLEICHER - Chicago IL, US
David H. BARAD - Closter NJ, US
David H. BARAD - Closter NJ, US
International Classification:
A61K 47/46, A61P 35/00, C12Q 1/68
US Classification:
514789, 435 612
Abstract:
A method of screening a human for risk of malignancies is disclosed. The method may include isolating the human's FMR1 gene, wherein the FMR1 gene has a first allele and a second allele, measuring the number of triple CGG repeats on each of the first and second alleles, wherein the measuring step is conducted through use of an assay, and identifying the human as at risk for cancer when the triple CGG repeat number for at least one of the first and second alleles is less than 26.
Androgen Treatment In Females
US Patent:
8501718, Aug 6, 2013
Filed:
Oct 7, 2009
Appl. No.:
12/575426
Inventors:
Norbert Gleicher - Chicago IL, US
David H. Barad - Closter NJ, US
Dwyn V. Harben - Bryn Mawr PA, US
David H. Barad - Closter NJ, US
Dwyn V. Harben - Bryn Mawr PA, US
Assignee:
American Infertility of New York - New York NY
International Classification:
A01N 45/00, A61K 31/56
US Classification:
514169, 514177
Abstract:
The present invention is directed to a method of improving ovarian reserve in a human female with diminished ovarian reserve as measured by the female's anti-Müllerian hormone level. The method may include evaluating a first anti-Müllerian hormone level of the female, administering dehydroepiandrosterone to the female for at least about one month, and evaluating a second anti-Müllerian hormone level of the female, wherein the second anti-Müllerian hormone level is greater than the first anti-Müllerian hormone level.